Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) reported Q4 EPS of ($0.72), $0.06 better than the analyst estimate of ($0.78). Revenue for the quarter came in at $13.53 million versus the consensus estimate of $11.41 million.

For earnings history and earnings-related data on Arcutis Biotherapeutics, Inc. (ARQT) click here.